Background and purpose: Accumulated evidence suggests that oxidative stress is involved in amyloid b (Ab)-induced cognitive dysfunction. Silibinin (silybin), a flavonoid derived from the herb milk thistle (Silybum marianum), has been shown to have antioxidative properties; however, it remains unclear whether silibinin improves Ab-induced neurotoxicity. In the present study, we examined the effect of silibinin on the memory impairment and accumulation of oxidative stress induced by Ab25-35 in mice. , once a day, p.o.) was started immediately after the injection of Ab25-35. Locomotor activity was evaluated 6 days after the Ab25-35 treatment, and cognitive function was evaluated in a Y-maze and novel object recognition tests 6-11 days after the Ab25-35 treatment. The levels of lipid peroxidation (malondialdehyde) and antioxidant (glutathione) in the hippocampus were measured 7 days after the Ab25-35 injection. Key results: Silibinin prevented the memory impairment induced by Ab25-35 in the Y-maze and novel object recognition tests. Repeated treatment with silibinin attenuated the Ab25-35-induced accumulation of malondialdehyde and depletion of glutathione in the hippocampus.
Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with global mental dysfunction and impairment of cognitive function (Palmer, 2002) . Common pathological features of AD are senile plaques, neurofibrillary tangles and neuronal loss in the medial temporal lobe structures and cortical areas of the brain (Blennow et al., 2006) . The deposition of amyloid b (Ab) peptide in neuritic plaques is the defining feature for diagnosis of AD, and the level of Ab peptide correlates well with the extent of cognitive impairment (Naslund et al., 2000) . Ab, a spontaneously aggregating peptide of 39-43 amino acids, is the primary protein component of senile plaques, a pathological hallmark of AD in the brain (Shen et al., 2002) . Several studies have demonstrated that oxidative stress is involved in Ab-induced neurotoxicity and the progression of AD (Schubert et al., 1995; Yankner, 1996) . In particular, Ab fragment [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] seems to be responsible for toxic and oxidative events leading to brain damage, such as oxidative stress-mediated changes in hippocampal long-term potentiation (Trubetskaya et al., 2003) , protein nitration, induction of inducible nitric oxide synthase (Tran et al., 2001; Alkam et al., 2008) and protein oxidation in fibroblasts derived from AD patients (Choi et al., 2003) .
In animal experiments, intrahippocampal or i.c.v. injections of Ab25-35 induced histological and biochemical changes, learning deficits (Maurice et al., 1996; Meunier et al., 2006; Alkam et al., 2008) and dysfunction of the cholinergic system, which plays an important role in the cognitive deficits associated with aging and neurodegenerative diseases (Tran et al., 2001) . Thus, Ab25-35-injected animals are useful models for understanding the pathogenesis and progression of AD, and for evaluating new therapeutic agents for AD (Maurice et al., 1996) .
Several synthetic antioxidants are available, but there is a growing trend towards the use of natural products (polyphenols, flavonoids, vitamins, carotenes and lycopenes) as antioxidants. Of these, bioflavonoids are a ubiquitous group of polyphenolic substances present in most plants (Nijveldt et al., 2001) . Silibinin (silybin) is a flavonoid derived from the herb milk thistle (Silybum marianum) (Kren and Walterová, 2005;  Figure 1A ) and used as a hepatoprotectant in the clinical treatment of liver disease (Kren and Walterová, 2005) . Silibinin seems to protect against oxidative stress as it has been reported to decrease lipid peroxidation, a sensitive marker of oxidative lipids, in liver microsomes and isolated hepatocytes (Bosisio et al., 1992) . Furthermore, it has been demonstrated that the antioxidative activity of silibinin is related to the scavenging of free radicals (De Groot and Rauen, 1998; Trouillas et al., 2008) and activation of antioxidative defenses: increases in cellular glutathione (GSH) content (Valenzuela et al., 1989) and superoxide dismutase levels (Müzes et al., 1991) . These findings suggest that silibinin could attenuate oxidative stress-induced brain dysfunction. In fact, there are a few reports that silymarin, a mixture of flavonoids present in milk thistle and whose main component is silibinin, has protective effects on the central nervous system against ethanol-induced brain injury (La Grange et al., 1999) and lipopolysaccharide-induced neurotoxicity (Wang et al., 2002) . However, it remains unclear whether silibinin protects against Ab-induced neurotoxicity.
In the present study, to confirm the usefulness of silibinin against Ab-induced neurotoxicity, we investigated whether silibinin prevents memory impairment in an Ab 25-35-injected animal model of AD. Moreover, we examined the protective effect of silibinin on oxidative events indicated by an increase in malondialdehyde (MDA), the end product of lipid peroxidation, and decrease in GSH, an endogenous antioxidant, in the hippocampus of Ab25-35-injected mice.
Methods

Animals
Male ICR mice, 5 weeks old at the beginning of experiments, were obtained from Japan SLC Inc. (Shizuoka, Japan). They were housed in plastic cages and kept in a regulated environment (23 Ϯ 0.5°C, 50 Ϯ 5% humidity) with a 12/12 h light/ dark cycle (lights on from 08.00 h to 20.00 h). The mice received food (CE2; Clea Japan Inc., Tokyo, Japan) and water ad libitum. Behavioural experiments were carried out in a sound-proof and air-regulated experimental room, to which mice were habituated for at least 1 h. All experiments were performed in accordance with the Guidelines for Animal Experiments of the Faculty of Pharmaceutical Sciences Meijo University and the Guiding Principles for the Care and Use of Laboratory Animals approved by the Japanese Pharmacological Society (2006) . The procedures involving animals and their care conformed to the international guidelines set out in the National Institutes of Health's Guide for the Care and Use of Laboratory Animals.
I.c.v. injection
Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] was dissolved in distilled water at a concentration of 1 mM as a stock solution and stored at -20°C. In the present study, the concentration and dose were selected according to a previous study (Maurice et al., 1996) . It has been shown that Silibinin and memory deficits P Lu et al i.c.v. administration of Ab25-35 at the dose of 9 nmol leads to memory impairment with severe neurotoxicity in mice, and at the dose of 3 nmol produces mild brain dysfunction, whereas it fails to cause cognitive deficits at the dose of 1 nmol (Maurice et al., 1996) . The Ab25-35 (3 nmol = 3 mg) is greatly diluted by cerebrospinal fluid and interstitial fluid to a level of about 6000 ng·g -1 tissue, which is in the range of tissue levels (21.0-89.1 ng·g -1 tissue: water-soluble Ab; 377.3-3000.0 ng·g -1 tissue: water-insoluble Ab) found in brains of AD patients (Kuo et al., 1996) , when it diffuses throughout the whole brain (average weight is about 0.5 g). Moreover, a certain amount of Ab25-35 is cleared or moved out from brain, which further decrease its concentration. Therefore, Ab25-35 at the dose of 3 nmol was used in this study. The Ab25-35 was aggregated, or 'aged', by incubating it in distilled water at 37°C for 4 days. Aggregated Ab25-35 [3 nmol·(3 mL)
-1 ] or distilled water (3 mL) was injected i.c.v., as described previously (Maurice et al., 1996) . Briefly, a microsyringe with a specially made 28-gauge stainless steel needle, 3 mm in length, was used for microinjections. Mice were anaesthetized lightly with ether, and the needle was inserted unilaterally 1 mm to the right of the midline point equidistant from each eye, at an equal distance between the eyes and the ears and perpendicular to the plane of the skull (A, -0.22 mm; L, 1 mm from the bregma; V, 2.5 mm from the skull). Ab25-35 [3 nmol·(3 mL)
-1 ] or distilled water (3 mL) was delivered gradually within~3 s. Mice exhibited normal behaviour within 1 min after injection. In preliminary experiments the injection site was confirmed by injecting Indian ink. Neither insertion of the needle nor injection of the distilled water had a significant influence on survival, behavioural responses or cognitive functions.
Drug treatment
Silibinin was suspended in a 0.3% carboxymethylcellulose solution. Mice were administered silibinin (2, 20 and 200 mg·kg -1 , p.o.) or the 0.3% carboxymethylcellulose solution by oral gavage 60 min before the Y-maze test and the training session of the novel object test. All compounds were administered systemically in a volume of 0.01 mL·g -1 body weight ( Figure 1B ).
Behavioural procedures
Previously it has been shown that acute exposure to aged Ab25-35 induces apoptosis-mediated neuronal toxicity during 6 days of incubation in hippocampal cultures, and cognitive dysfunction in several learning and memory tests in mice (Maurice et al., 1996) . The behavioural tests were started 6 days after the Ab25-35 injection and were carried out sequentially according to the experimental schedule shown in Figure 1B . The present study was conducted in a blind manner.
Measurement of locomotor activity
The measurement of locomotor activity in a novel environment was carried out on day 6 after the start of silibinin administration. Spontaneous locomotor activity was measured as previously reported with a minor modification (Miyamoto et al., 2001) . Mice were placed individually in a transparent acrylic cage with a black frosted Plexiglas floor (45 ¥ 26 ¥ 40 cm) for 90 min, and locomotor activity was measured in 5 min intervals by using digital counters with infrared sensors. The system was equipped with photosensor frames in the side walls. Locomotor activity was defined as the total number of beam cuts due to horizontal movement measured by the photosensors. The acrylic cage was wiped with a paper towel between uses and kept clean.
Spontaneous alternation in a Y-maze test
This behavioural test was performed 6 days after the Ab [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] injection, according to a previous study (Mouri et al., 2007) , with minor modifications. The maze was made of black painted wood; each arm was 40 cm long, 12 cm high, 3 cm wide at the bottom and 10 cm wide at the top. The arms converged at an equilateral triangular central area that was 4 cm at its longest axis. Each mouse was placed at the centre of the apparatus and allowed to move freely through the maze for 8 min. The series of arm entries was recorded visually. Alternation was defined as successive entry into the three arms on overlapping triplet sets. Alternation behaviour (%) was calculated as the ratio of actual alternations to possible alternations (defined as the number of arm entries minus two) multiplied by 100.
Novel object recognition test
The novel object recognition test was performed 7-11 days after the Ab 25-35 injection, according to a previous study (Mouri et al., 2007) , with minor modifications. The task consisted of three sessions: habituation, training and retention. Each mouse was individually habituated to the box (30 ¥ 30 ¥ 30 high cm), with 10 min of exploration in the absence of objects for 3 days (habituation session). During the training session, two objects were placed in the middle of the box. A mouse was then placed midway at the front of the box, and total time spent exploring the two objects was recorded for 10 min. During the retention session, animals were placed back into the same box 24 h after the training session, in which one of the familiar objects used during training was replaced with a novel object. The animals were then allowed to explore freely for 5 min, and the time spent exploring each object was recorded. Throughout the experiments, the objects were used in a counterbalanced manner in terms of their physical complexity and emotional neutrality. A preference index, a ratio of the amount of time spent exploring any one of the two objects (training session) or the novel object (retention session) over the total time spent exploring both objects, was used to measure cognitive function.
Determination of lipid peroxidation level
Malondialdehyde was measured with a thiobarbituric acidreactive substance (TBARS) assay kit. Briefly, the hippocampus was isolated and homogenized in cooled RIPA buffer (50 mM Tris-Cl pH 7.4, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS,1 mM PMSF, 1 mM Na 3VO4, 1 mM NaF and protease inhibitor cocktail). Tissue homogenate from the Silibinin and memory deficits 1272 P Lu et al hippocampus was incubated with 8.1% sodium dodecylsulphate for 10 min followed by the addition of 20% acetic acid (pH 3.5). The reaction mixture was incubated with 0.6% thiobarbituric acid at 99°C for 1 h. After being cooled, the mixture was centrifuged at 1600¥ g for 10 min at 4°C. The absorbance was measured by using a plate reader (Bio-Rad 550) at 540 nm. MDA content was expressed as mmol·g -1 tissue.
Determination of glutathione content
A GSH assay kit was used for detecting GSH in the hippocampus. Briefly, the hippocampal tissues were isolated and homogenized in cold buffer (0.05 M phosphate, pH 6-7, containing 1 mM EDTA). The homogenates were centrifuged at 10 000¥ g for 15 min at 4°C, and the supernatant was subsequently incubated with MES buffer (0.2 M 2-(Nmorpholino)ethanesulphonic acid buffer, 0.1 M phosphate and 2 mM EDTA, pH 6.0), cofactor mixture, enzyme mixture and DTNB [5,5′-dithiobis (2-nitrobenzoic acid)] in the dark on the orbital shaker at room temperature for 30 min. Absorbance at 405 nm was measured by using a plate reader (BioRad 550), and GSH content was calculated as mmol·g -1 tissue.
Statistical analysis
All data are expressed as the means Ϯ s.e.mean. Statistical differences among the experimental groups were tested by using a one-or two-way analysis of variance (ANOVA) for behavioural tests, and Tukey's post hoc test was employed for multiple comparisons. P-values less than 0.05 were accepted as significant.
Materials
Ab25-35 was purchased from Bachem (Bubendorf, Switzerland); silibinin from Panjin Green Biological Development Co., Ltd.
(Panjin, China); digital counters with infrared sensors Scanet SV-10 (Melquest Ltd., Toyama, Japan); TBARS assay kit and GSH assay kit, Cayman (Ann Arbor, MI, USA).
Results
Effect of silibinin on locomotor activity
The counts of spontaneous locomotor activity of mice were measured on day 6 after Ab25-35 injection. There were no significant differences in the time course of locomotor activity (Figure 2A ).
Effect of silibinin on short-term memory impairment induced by Ab25-35 in Y-maze test
We evaluated the effects of silibinin on impairment of shortterm memory 6 days after the Ab25-35 injection in a Y-maze test. Ab25-35-injected mice showed significantly reduced spontaneous alternation behaviour compared with vehicleinjected mice (P < 0.05, Figure 2B ). Treatment with silibinin (2, 20 and 200 mg·kg -1 ) dose-dependently attenuated the impairment of spontaneous alternation behaviour in Ab25-35 injected mice [F(5, 66) = 6.325, P < 0.05, Figure 3 ]. Silibinin doses of 20 and 200 mg·kg -1 significantly prevented Ab25-35-induced memory impairment (P < 0.05, Figure 3 ). There was no significant difference in the number of arm entries among the groups [F(4, 66) = 0.463, P = 0.763: data not shown]. Silibinin did not affect spontaneous alternation ( Figure 2B ) and the number of arm entries (data not shown) in mice injected with distilled water. Results are expressed as the means Ϯ s.e.mean (A: n = 8, B: n = 13-15) and were analysed by a one or two-way ANOVA, followed by Tukey's test for multiple comparisons. #P < 0.05 versus carboxymethylcellulose (CMC)-treated, distilled water-injected mice; *P < 0.05 versus CMC-treated, Ab25-35-injected mice.
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Effect of silibinin on recognition memory impairment induced by Ab25-35 in the novel object recognition test
We evaluated the effect of silibinin on impairment of visual recognition memory 7 days after the Ab25-35 injection in a novel object recognition test. In the training session, mice injected with Ab25-35 or distilled water spent equal amounts of time exploring either of the two objects ( Figure 3A) , showing there was no biased exploratory preference in either group of animals. In addition, total time spent in the exploration of objects in the training and retention sessions did not differ between the groups injected with Ab25-35 or distilled water ( Figure 3B and D) . When the retention session was performed 24 h after the training session, the level of exploratory preference for the novel objects in the Ab25-35-injected mice was significantly decreased compared with that in the distilled water-injected mice (P < 0.05, Figure 3C ). Treatment with silibinin (2, 20 and 200 mg·kg -1 ) dose-dependently and significantly reversed the decreased level of exploration preference in the retention session in Ab25-35-injected mice [F(5, 66) = 16.195, P < 0.05, Figure 3C ]. Tukey's post hoc analysis revealed that silibinin at 200 mg·kg -1 significantly prevented the memory impairment in Ab25-35-injected mice (P < 0.05, Figure 3C ). Treatment with silibinin did not affect either the level of exploratory preference for the objects or the total exploration time in either the training or retention sessions for the mice injected with Ab25-35 or those injected with distilled water (Figure 3A-D) . Silibinin and memory deficits 1274 P Lu et al examined the effect of silibinin on the levels of MDA in the hippocampus 7 days after the Ab25-35 injection. A significant increase in the level of MDA was observed in the hippocampus of Ab25-35-injected mice as compared with levels in the control group [F(5, 34) = 8.281, P < 0.05, Figure 4A ]. Treatment with silibinin (200 mg·kg -1 ) significantly prevented the increase of MDA levels in the hippocampus of Ab25-35-treated mice (P < 0.05, Figure 4A ). In contrast, Ab25-35-injected mice showed a significant decrease of GSH levels in the hippocampus compared with the control mice. Treatment with silibinin (2, 20 and 200 mg·kg -1 ) dose-dependently prevented the decrease in GSH levels in the hippocampus of Ab25-35-injected mice [F(5, 34) = 9.351, P < 0.05, Figure 4B ]. Tukey's post hoc analysis indicated a significant effect of silibinin at the dose of 200 mg·kg -1 (P < 0.05, Figure 4B ). However, silibinin did not affect levels of MDA and GSH in the hippocampus of mice injected with distilled water (Figure 4A and B).
Effect of silibinin on the MDA and GSH levels in the hippocampus of Ab25-35-injected mice
Discussion and conclusions
In the present study, we examined the effect of silibinin on the memory impairment induced by Ab25-35 in mice. Silibinin prevented Ab25-35-induced impairment of short-term and recognition memory in the Y-maze and novel object recognition tests respectively. Furthermore, silibinin prevented the accumulation of lipid peroxide (MDA) and decrease of antioxidant (GSH) in the hippocampus after the Ab25-35 treatment. To our knowledge, this is the first study to show that silibinin protects against Ab-injected neurotoxicity by regulating oxidative stress in the brain.
The accumulation of Ab proteins is highly toxic to primary and other cell lines (Kim et al., 2007; Nie et al., 2008) . Ab25-35 is most toxic Ab fragment that has been detected in the brain of AD patients (Pike et al., 1995; Kubo et al., 2002; Zameer et al., 2006) . Ab 25-35 is the core fragment of full-length Ab and possesses many of the characteristics of the full-length Ab peptide, including aggregative ability and neurotoxic properties such as learning and memory impairment, morphological alterations and cholinergic dysfunction (Pike et al., 1995; Tran et al., 2001; Kubo et al., 2002; Alkam et al., 2008) . Therefore, the effect of silibinin on Ab-induced neurotoxicity was evaluated in Ab25-35-injected mice. In the present study, Ab25-35-injected mice showed memory impairment in both the Y-maze and the novel object recognition tests. These results are consistent with our previous findings that Ab25-35 induces cognitive impairment in mice (Alkam et al., 2007; Tsunekawa et al., 2008) .
Silibinin dose-dependently and significantly prevented the impairment of short-term and recognition memory induced by Ab25-35. It is unlikely that the protective effect of silibinin is due to changes in motivation or sensorimotor function, as various motivations are involved in these behavioural tasks, and different skills are required for better performance in each task. Actually, silibinin had no effect on locomotor activity, number of arm entries in the Y-maze test and total time spent exploring objects in the novel object test. These results suggest that silibinin attenuates cognitive impairments in the Ab25-35-injected mice without affecting motor function, motivation and exploratory activity.
It has been proposed that oxidative stress plays a critical role in the development of AD (Smith et al., 1996) . Lipid peroxidation is one of the major outcomes of free radicalmediated injury that directly damages membranes and generates a number of secondary products including aldehydes, such as MDA, and 4-hydroxy-2-nonenal, ketones, etc. (Slater, 1984) . Analysis of AD brains demonstrates an increase in lipid peroxidation products in the amygdala, hippocampus and parahippocampal gyrus of the AD brain compared with Results are expressed as the means Ϯ s.e.mean (n = 6-7) and analysed by a one-way ANOVA, followed by Tukey's test for multiple comparisons. #P < 0.05 versus carboxymethylcellulose (CMC)-treated, distilled water-injected mice; *P < 0.05 versus CMC-treated, Ab25-35-injected mice.
Silibinin and memory deficits P Lu et al age-matched controls (Markesbery and Lovell, 1998) . Amyloid precursor protein transgenic mice, a genetic mouse model of AD, have shown a systemic increase in lipid peroxidation compared with wild-type littermates (Pratico et al., 2001) . MDA is the most abundant individual aldehyde resulting from lipid peroxidation and can be considered a marker of lipid peroxidation. To confirm the effect of silibinin on Ab-induced oxidative stress, we measured the levels of MDA in the hippocampus. Ab25-35 increased the levels of MDA in the hippocampus, suggesting that it caused lipid peroxidation. Treatment with silibinin prevented the accumulation of MDA induced by Ab25-35. Accordingly, these results suggest that the protective effect of silibinin on Ab25-35-induced memory impairment is related to an accumulation of oxidative stress in the hippocampus.
It has been proposed that Ab peptide impairs the antioxidative defenses in brain, which may contribute to the pathogenesis of AD (Mattson et al., 1998) . GSH is one of the most abundant intracellular non-protein thiols in the central nervous system, where it plays a major antioxidative role within both neurones and non-neuronal cells. In the present study, Ab25-35 decreased the level of GSH in the hippocampus, consistent with reports of the depletion of GSH in the brain of AD patients (Aksenov and Markesbery, 2001) . Furthermore, the Ab25-35-induced decrease in the level of GSH was prevented by treatment with silibinin, indicating that the protective effect of silibinin on Ab25-35-induced cognitive impairment involves the activation of antioxidative defenses.
Although the mechanism by which silibinin regulates Ab25-35-induced oxidative stress remains to be determined, there are several possible explanations. Firstly, as a polyphenolic flavonoid, silibinin has strong free radical-scavenging activity (Trouillas et al., 2008) . Silibinin reacts with a damaging free radical and forms a flavonoid radical, which has greater stability, and then breaks the free radical chain reaction (Weber et al., 2006) . It is possible that silibinin prevents oxidative damage directly by scavenging free radicals. Secondly, it has been demonstrated that silibinin has a metal-chelating effect (Borsari et al., 2001) . The neurotoxicity of Ab is mediated by AbCu 2+ or AbFe 3+ forming H2O2, which generates lipid peroxidation adducts, protein carbonyl modifications and nucleic acid adducts in various cellular compartments. Thus, metal ions mediate the oxidative stress mechanism of Ab toxicity. Incubation with the Fe 3+ chelator desferrioxamine has been shown to decrease the toxicity of synthetic Ab (Rottkamp et al., 2001) . It is possible that silibinin attenuates the Ab-induced oxidative stress in the hippocampus by chelating metal ions.
Thirdly, oxidative stress occurs when the antioxidative defenses are broken down by the overproduction of reactive oxygen species. Expanding the antioxidant capacity of neurones will provide a potential strategy to protect neurones from oxidative damage (Ahlemeyer et al., 2001; AlcarazZubeldia et al., 2001) . Silibinin is known to induce the expression of antioxidative enzymes (Valenzuela et al., 1989; Müzes et al., 1991) . Therefore, it is possible that silibinin prevents oxidative damage indirectly by activating antioxidative systems including GSH biosynthesis. It remains to be determined whether silibinin affects antioxidant enzymes in the hippocampus of Ab-injected mice.
As another possible mechanism, silibinin may directly suppress aggregation of Ab or stability of aggregated Ab, so affecting Ab conformation in the brain. Polyphenols, such as silibinin, have shown to inhibit aggregation of Ab and exhibit significant destabilizing activity on aggregated Ab (Ono et al., 2003; Porat et al., 2006; Shoval et al., 2007) . Because aggregated Ab 25-35 was used in this study, it is possible that silibinin may affect the degradation of aggregated Ab. However, further studies are needed to clarify the effect of silibinin on the conformation and levels of Ab.
The results from the present study confirm, for the first time, that silibinin could alleviate the memory deficits induced by Ab25-35 in mice. The effect of silibinin may be attributed to the prevention of oxidative damage in the hippocampus, measured in terms of the amount of peroxidized lipid and the level of GSH. As a therapeutic agent, silibinin is well tolerated and largely free of adverse effects and has few negative drug interactions (Jacobs et al., 2002) . Therefore, silibinin is a potential candidate for further preclinical study aimed at the treatment of cognitive deficits in AD.
